Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Cullinan Oncology, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1study of CLN-978 in relapsed/refractory B Cell non-Hodgkin lymphoma Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 CAMBRIDGE, Mass., August 10, 2023 -- Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and an..."
06/06/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023"
05/19/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/11/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results"
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 16.4% stake in Cullinan Oncology, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6.2% stake in Cullinan Oncology Inc.
02/03/2023 SC 13G BlackRock Inc. reports a 5.5% stake in Cullinan Oncology
01/19/2023 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock",
"Exchange Agreement, by and among Cullinan Oncology, Inc. and the Stockholders named therein"
10/25/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2022 10-K Annual Report for the period ended December 31, 2021
03/17/2022 8-K Quarterly results
03/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy